- Home
- ELAB vs GCTK Comparison
ELAB vs GCTK Comparison
Compare ELAB & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- GCTK
- Stock Information
- Founded
- ELAB 2020
- GCTK 2001
- Country
- ELAB United States
- GCTK United States
- Employees
- ELAB N/A
- GCTK N/A
- Industry
- ELAB
- GCTK Medical/Dental Instruments
- Sector
- ELAB
- GCTK Health Care
- Exchange
- ELAB Nasdaq
- GCTK Nasdaq
- Market Cap
- ELAB 3.2M
- GCTK 3.3M
- IPO Year
- ELAB 2023
- GCTK N/A
- Fundamental
- Price
- ELAB $9.61
- GCTK $7.48
- Analyst Decision
- ELAB
- GCTK
- Analyst Count
- ELAB 0
- GCTK 0
- Target Price
- ELAB N/A
- GCTK N/A
- AVG Volume (30 Days)
- ELAB 128.7K
- GCTK 197.4K
- Earning Date
- ELAB 11-13-2025
- GCTK 11-13-2025
- Dividend Yield
- ELAB N/A
- GCTK N/A
- EPS Growth
- ELAB N/A
- GCTK N/A
- EPS
- ELAB N/A
- GCTK N/A
- Revenue
- ELAB N/A
- GCTK N/A
- Revenue This Year
- ELAB N/A
- GCTK N/A
- Revenue Next Year
- ELAB N/A
- GCTK N/A
- P/E Ratio
- ELAB N/A
- GCTK N/A
- Revenue Growth
- ELAB N/A
- GCTK N/A
- 52 Week Low
- ELAB $4.29
- GCTK $4.22
- 52 Week High
- ELAB $903.86
- GCTK $2,928.00
- Technical
- Relative Strength Index (RSI)
- ELAB 78.56
- GCTK 54.95
- Support Level
- ELAB $5.00
- GCTK $7.02
- Resistance Level
- ELAB $6.90
- GCTK $9.05
- Average True Range (ATR)
- ELAB 0.51
- GCTK 0.54
- MACD
- ELAB 0.15
- GCTK 0.06
- Stochastic Oscillator
- ELAB 96.39
- GCTK 53.57
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.